Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Vaccinex, Inc. VCNX

8 fiscal years on record · USD · FY2024 reported · SEC filings only
$601,000
▲ 5.4% YoY
$-18.6M
$-16.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. Our lead platform technology is our SEMA4D antibody platform which includes our lead product candidate, pepinemab, which is currently in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer, through our efforts or through investigator-sponsored trials. Our ActivMAb® antibody discovery platform is a proprietary human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses. Pepinemab is a humanized monoclonal antibody that binds and blocks the signaling activity of SEMA4D. VX5 was generated by our ActivMAb platform for preclinical development related to autoimmune disorders.

Written from the business description in VACCINEX, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2025. Every sentence was checked against that document before publication.

Growth

USD 601,000.00
Revenue, FY2024 · full 8-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.6 · Net income -18.6
-15M-30M
2017202020232024
Compound annual growth
−12.6%
+2.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.8% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -3117.3%
-10000%-20000%
201720202024
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -16.2
-15M-30M
201720202024

Total assetsUSD 2.6M
CashUSD 1.1M
Gross debtUSD 25,000.00
Net debtUSD -1.1M
Current ratio0.50×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VCNX, 8-year financial record
Metric 20242023202220212020201920182017
Revenue $B0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−8.88−43.68−98.05−0.78−1.54−2.47−5.65−19.90
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %——−314.4—————
Shares out B0.000.000.000.030.020.010.010.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 32 reconciliationsAUDITED

Reconciled in 7 of the 8 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image